Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com
  • 5.0 (1)
  • Health & Fitness

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. 1d ago

    A 360° Glaucoma Procedure Beat Simple Needle Goniotomy at 2 Years — How Effective Is GATT Really?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/a-360-glaucoma-procedure-beat-simple-needle-goniotomy-at-2-years-how-effective-is-gatt-really Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: A 360° Glaucoma Procedure Beat Simple Needle Goniotomy at 2 Years — How Effective Is GATT Really? Introduction Opening the eye’s natural drainage pathway all the way around sounds as though it should lower pressure more than opening only one small section. A randomized trial published on September 28, 2026 offers a rare direct comparison: gonioscopy-assisted transluminal trabeculotomy, which opens the drainage pathway through 360 degrees, versus a 90-degree procedure using a bent needle. At two years, the full-circle procedure had better average pressure and medication results. But the trial does not prove that treating more degrees alone caused the advantage. The treatments differed in both extent and technique, and the study was small. Its results support gonioscopy-assisted transluminal trabeculotomy as a promising option for selected patients—not as a guarantee of very low pressure or freedom from future treatment. The 2026 randomized trial by Ayub and Costa () What the randomized trial actually studied The trial enrolled 45 eyes from 34 adults at two centers in Brazil. Participants had mild-to-moderate primary open-angle glaucoma, were 40 to 80 years old, had already undergone cataract surgery, and were using no more than three pressure-lowering medicines. Their treated pressure had to be at least 18 millimeters of mercury at two visits. The researchers assigned 23 eyes to gonioscopy-assisted transluminal trabeculotomy (GATT) and 22 to bent ab interno needle goniotomy (BANG). Patients were masked to their procedure, but the surgeons and examiners could identify it. The same experienced surgeon performed all operations. In the full-circle procedure, the surgeon passed a suture around Schlemm’s canal and pulled it through, opening the trabecular meshwork through 360 degrees. The needle procedure removed a strip of tissue over approximately 90 degrees of the nasal angle. So this was not a comparison of the same operation at two different widths: both the instrument and the amount of tissue treated differed. Trial methods and eligibility criteria () Baseline pressure: two different starting points Before surgery, the average pressure while patients were still using their medicines was 19.87 millimeters of mercury in the GATT group and 21.18 in the BANG group. After a medication washout, the averages were much higher and almost identical: 25.43 and 25.55, respectively. The difference between the groups’ treated pressures was not statistically significant, but it matters when interpreting percentage reductions. The average medication burden was also similar: 2.35 medicines in the GATT group and 2.41 in the BANG group. Participants were mostly older adults, with an average age of about 73; the average visual-field loss was mild, and all eyes were pseudophakic, meaning they had an artificial lens after cataract surgery. Baseline data reported for the trial () Two-year results: GATT did better, but the details matter At 24 months, average pressure was 15.41 millimeters of mercury after GATT and 17.79 after BANG. The paper reported reductions from the on-treatment baseline of 22.44% and 16.0%, respectively. Because the GATT group started with a treated average about 1.3 millimeters lower, the difference in the absolute change from those baselines was smaller than the endpoint-pressure gap: approximately 4.46 millimeters of reduction for GATT and 3.39 millimeters for BANG, or roughly 1.1 millimeters more reduction for GATT. The clearest difference was medication use. At two years, the GATT group averaged 0.71 medicines, down from 2.35, while the BANG group averaged 2.26, down from 2.41. That is a reported reduction of 69.78% versus 6.22%. Eleven GATT eyes and two BANG eyes were medication-free. The trial’s “complete success” measure was stricter than simply reaching a particular pressure: an eye needed to be at or below 18 millimeters of mercury, have at least a 20% reduction, and be off medication. “Qualified success” used the same pressure criteria but allowed medication, without increasing the number used at baseline. At 24 months, the paper reported 55.0% complete success after GATT versus 4.5% after BANG. Qualified success was 64.7% versus 13.6% in the article’s results text; its abstract gives 11.4% for BANG. That small inconsistency is worth noting rather than smoothing over. Four GATT eyes reached 12 millimeters of mercury or lower, compared with none after BANG. Four out of 23 randomized GATT eyes is about 17%; four out of 17 GATT eyes completing follow-up is about 24%. Those are simple count-based proportions, not a robust estimate of what an individual patient’s chance would be. The trial’s Kaplan–Meier estimates and its raw eye counts use different methods and denominators. Two-year pressure, medication, target, and success results () Follow-up measurements Patients were scheduled for visits on postoperative days 1, 7, 15, 30, 60, 90, 180, 360, 540, and 720. The journal article’s searchable main text gives exact average pressures at inclusion and at 12 and 24 months. Earlier visit averages were also reported in a conference abstract from the same study. The table below shows those available interim values, with the peer-reviewed journal article’s numbers used for the final 24-month row. The conference report and final paper differ slightly in some late values; the final paper should take precedence. Neither source’s summary gives exact day-15 and day-60 averages. For the full table, please open this article on visualfieldtest.com. Pressure is in millimeters of mercury; figures after ± are standard deviations. The day-1 through day-540 values come from the conference report; final 24-month values come from the journal article. Conference report Final journal article () The pressure rise at day 30 in both groups is a reminder that early postoperative readings can fluctuate. In this trial, medicines were not restarted until day 30; afterwards, treatment was reintroduced under a specified protocol if pressure remained above 18 at consecutive visits. Early and late averages therefore need to be interpreted in light of the medication schedule, not as measurements taken under identical conditions at every visit. Trial follow-up and medication protocol () Loss to follow-up, additional procedures, and safety By 24 months, 19 of 22 BANG eyes and 17 of 23 GATT eyes had completed follow-up. Three BANG eyes left the protocol because they needed additional glaucoma surgery. Six GATT eyes did not complete it: four needed additional surgery, one had a retinal detachment at day 30, and one patient died. Seven eyes had a reoperation: three BANG eyes and four GATT eyes. All three BANG reoperations were bleb needlings; in the GATT group, three were needlings and one was a trabeculectomy. The trial reported no statistically significant difference between groups. Needling is a procedure to revise an existing filtering bleb, so these events should not be read as seven newly created blebs from the angle operations themselves. The study’s failure definition included additional glaucoma surgery. Follow-up and reoperation results () At least one complication was recorded in 12 BANG eyes (54.5%) and 17 GATT eyes (73.9%). Iris damage was the most common complication during surgery, and transient hyphema—blood in the front chamber of the eye—was the most common early postoperative problem. One GATT eye had a total hyphema on day one; it cleared within a week without intervention. The retinal detachment occurred 30 days after GATT, but one event in a small study cannot establish that the operation caused it. The article also reported a BANG eye with persistent corneal edema and cystoid macular edema associated with vitreous prolapse and a poorly positioned artificial lens. Some eyes in both groups showed notable reductions in corneal endothelial-cell counts. At two years, average counts were 1,561.88 cells per square millimeter after GATT and 1,477.56 after BANG; the difference between groups was not statistically significant. At least a 20% reduction occurred in 30.4% of GATT eyes and 22.7% of BANG eyes. These small-sample findings warrant follow-up; “no significant difference” does not establish that either procedure has no effect on the cornea. Complications and endothelial-cell results () Does opening more degrees produce more pressure reduction? Why a 360-degree opening might help The trabecular meshwork is part of the eye’s main fluid-drainage route. In open-angle glaucoma, resistance in this pathway is often too high. GATT opens the meshwork around the full circumference of Schlemm’s canal, whereas the trial’s BANG procedure treated about 90 degrees. A wider opening could help by reducing resistance over a larger area, reaching more of the eye’s drainage channels, and providing alternative routes if some regions drain poorly. Outflow is uneven around the eye, so a small opening may happen to reach a less useful region—or it may reach a particularly effective one. Healing and scarring could also affect how long any opening stays useful. These are plausible explanations, not mechanisms proven by this trial. Trial discussion of treatment extent and regional drainage () The broade Support the show

    A 360° Glaucoma Procedure Beat Simple Needle Goniotomy at 2 Years — How Effective Is GATT Really?

  2. 2d ago

    The Largest Glaucoma Genome Study Yet Found 29 New Genetic Clues — Could Existing Drugs Target Some of Them?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-largest-glaucoma-genome-study-yet-found-29-new-genetic-clues-could-existing-drugs-target-some-of-them Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: The Largest Glaucoma Genome Study Yet Found 29 New Genetic Clues — Could Existing Drugs Target Some of Them? The short answer is possibly—but the study did not identify a ready-made glaucoma drug. It found genetic associations that point toward several plausible disease mechanisms, including extracellular-matrix remodeling, aqueous-fluid outflow, cellular stress responses and retinal ganglion-cell survival. Among the four highlighted drug targets, the mammalian target of rapamycin pathway has the strongest combination of genetic, experimental and drug-delivery evidence. Even there, the right direction and amount of treatment remain uncertain. A critical distinction: a gene associated with glaucoma is not automatically a treatment target. The genetic finding may not reveal what the variant does, which eye cell it affects, or whether a drug should increase or decrease the gene’s activity. The paper itself cautions that, for most of these associations, pharmacological direction cannot yet be predicted. () This article distinguishes established evidence—what the studies directly report—from strong inference and informed speculation about possible treatments. What the study actually found The Communications Biology paper was published online on September 23, 2026. Its early-access version is peer reviewed but still described by the publisher as an article in press that may receive further edits. It is a genetic-association study, not a clinical trial. () Cohorts and ancestry For the full table, please open this article on visualfieldtest.com. The discovery and replication sequencing analyses were restricted to participants of European ancestry. The paper says 464,778 European-ancestry participants made up about 95% of its UK Biobank whole-genome-sequencing resource. The All of Us replication sample was also European ancestry. FinnGen represents a Finnish population, while the Million Veteran Program is ancestrally diverse overall, but the study’s cited open-angle-glaucoma analysis used its European-ancestry results. Thus, the large headline sample does not mean that the principal discovery and replication findings were tested across equally large, diverse ancestry groups. () The authors also report a preliminary UK Biobank pan-ancestry analysis that found 15 additional significant variants—11 rare and four common. They had external replication evidence for only one of those, a common variant near ADGRB2. The authors note that many signals were not present or testable in current external datasets. () Important caveat: the replication phenotype was broader than the discovery phenotype In UK Biobank, cases were identified from self-reported glaucoma and medical-record codes, with secondary forms excluded. In All of Us, the researchers used medical-record codes for glaucoma because that definition had more cases and greater statistical power than the smaller primary open-angle glaucoma-specific definition. This means the replication check was not a perfect match to the primary open-angle glaucoma discovery phenotype. FinnGen used a primary open-angle glaucoma endpoint; the Million Veteran Program used an open-angle-glaucoma phenotype. () That does not invalidate the replication evidence, but it makes the word “replication” less straightforward than it may sound. A signal that appears in a broader glaucoma group is supportive; it is not the same as reproducing the exact association in an independently diagnosed primary open-angle glaucoma cohort. Sequencing, variant thresholds and statistical significance The UK Biobank genomes were sequenced on an Illumina NovaSeq 6000 platform at an average depth of about 32.5-fold. The researchers used GraphTyper-called single-nucleotide variants and insertions or deletions, applied quality filters, and used REGENIE, a method designed to account for population structure and relatedness. Single-variant analyses included variants with a minor allele count of at least five and tested variants within genes, including a one-kilobase margin; intergenic variants were excluded. () The paper categorizes variants with an effect-allele frequency below 1% as rare. For single-variant tests, genome-wide significance was P 5 × 10⁻⁸. For gene-based rare-variant tests, the threshold was P 2.5 × 10⁻⁶, based on correction for roughly 20,000 genes. The gene-based analysis used loss-of-function variants and, in another test, combined loss-of-function, missense and nearby regulatory variants. () For external checks, the authors looked up significant variants and genes in All of Us, FinnGen and the Million Veteran Program. If an exact rare variant was not available, they sometimes counted a significant variant elsewhere in the same gene region as support. The methods do not describe one uniform, strict replication threshold applied to every variant and gene. The paper’s “replicated or supported” label therefore covers different kinds and strengths of evidence. () The “29 new clues” were not 29 new genes The study reports 29 novel genome-wide significant rare-variant associations. That is not the same as finding 29 new glaucoma genes. The complete table contains 36 genome-wide significant rare variants, including established variants in MYOC and OPTN. A gene may contain a rare association without the study proving that the gene itself is the causal effector. () Among the highlighted novel rare variants were: For the full table, please open this article on visualfieldtest.com. The paper also confirmed known rare-variant associations in MYOC and OPTN. These confirmations help show that the analysis can recover established biology; they are not new treatment findings. () Gene-based testing identified six significant genes: DDR2, MYOC, LTBP2, MTOR, ANGPTL7 and FKBP9. The paper described new gene-based associations for DDR2, LTBP2, MTOR, ANGPTL7 and FKBP9, while MYOC is already an established glaucoma gene. The gene-based associations for DDR2 and LTBP2 came from loss-of-function variants; MTOR, ANGPTL7 and FKBP9 were identified using broader variant sets. () The paper also reported common-variant associations in 22 genes not previously reported as gene-level primary open-angle glaucoma associations. MAPT appears in a common-variant signal near the KANSL1/MAPT region. LYN, by contrast, is highlighted in connection with a rare single-variant association. These are different kinds of evidence and should not be treated as equally precise gene identifications. () What biology do the new signals point toward? The researchers examined gene-expression datasets from ocular tissues and cell types. They found evidence that many associated genes are expressed in trabecular-meshwork cells, Schlemm’s canal, retinal ganglion cells, retinal support cells, or optic-nerve and posterior-eye tissues. That supports biological plausibility, but expression does not prove that a gene causes glaucoma. The expression analyses were based on existing datasets, not new experiments in diseased human eyes. () The most plausible biological interpretations Aqueous outflow and intraocular pressure: LTBP2, ANGPTL7, DDR2, PRRX1 and TNS3 are plausible candidates for effects on connective tissue, cell attachment, extracellular matrix or outflow-pathway remodeling. The trabecular meshwork is a major site of resistance to aqueous-fluid drainage, and Schlemm’s canal helps carry that fluid out of the eye. () Retinal ganglion-cell resilience and axon health: MTOR, PRRC2C, METTL13/EEF1AKNMT and some of the other associated genes are plausible participants in cellular stress responses, protein production, or the survival of retinal neurons and their axons. Several associated genes were detectable in retinal ganglion cells or retinal support cells. () Metabolism and vascular biology: FMO3 is primarily a liver enzyme involved in metabolism of trimethylamine. The paper proposes a possible systemic route involving trimethylamine N-oxide and vascular function, but this is not evidence that the glaucoma-associated variant acts in the eye. () Glial and inflammatory biology: The paper found expression of genes including LYN, MTOR and PRRC2C in retinal Müller glia or astrocytes. These cells support retinal neurons and participate in stress responses. Expression alone cannot show whether their activity is protective or harmful in glaucoma. () Functional predictions are leads, not measurements The authors used AlphaGenome, a computational model that predicts effects on features such as gene regulation, chromatin accessibility and splicing. Among 29 novel rare variants analyzed, 12 had at least one predicted effect above the paper’s threshold in an eye-related tissue or cell type. Predictions for METTL13 and DNM3 included trabecular-meshwork effects; the FMO3 variant had a predicted splice-related effect. The authors state that they did not experimentally validate these predictions. A model-predicted increase or decrease in an assay track also does not, by itself, establish that the gene’s activity increased or decreased in the relevant living eye cell. () Four drug-highlighted genes: what might—and might not—be actionable? The paper used the Open Targets platform to identify genes with e Support the show

    The Largest Glaucoma Genome Study Yet Found 29 New Genetic Clues — Could Existing Drugs Target Some of Them?

  3. 4d ago

    Can Air Pollution Damage the Optic Nerve? A Large Review Links PM2.5 to Higher Glaucoma Risk

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-air-pollution-damage-the-optic-nerve-a-large-review-links-pm2-5-to-higher-glaucoma-risk Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can Air Pollution Damage the Optic Nerve? A Large Review Links PM2.5 to Higher Glaucoma Risk The short answer: Long-term exposure to fine particulate matter, or PM2.5, is associated with glaucoma in several populations, and there are plausible ways pollution could affect the eye’s blood supply and nerve cells. But the new European Society of Cataract and Refractive Surgeons analysis is available publicly mainly as a conference announcement—not a full methods paper. Its headline figures cannot yet be checked or translated reliably into a specific change in air pollution concentration. The evidence makes PM2.5 a credible candidate modifiable risk factor, not an established cause of glaucoma. It is reasonable to reduce avoidable exposure when doing so is practical, especially for general health. There is no evidence that an air purifier prevents glaucoma or slows vision loss. What the ESCRS 2026 analysis actually reported The study, presented on September 14, 2026, was titled “Smog and sight: epidemiological evidence on the link between air pollution and ocular aging: a comprehensive systematic review and meta-analysis.” The European Society of Cataract and Refractive Surgeons reported that it included 41 observational studies and data from millions of people, described as coming mainly from East Asia and the United Kingdom. The review considered glaucoma, cataract, and age-related macular degeneration, and examined fine and larger particulate matter, nitrogen dioxide, sulfur dioxide, ozone, and carbon monoxide. () The 41 studies were not reported as 41 glaucoma studies. They were the total for the review’s eye-disease outcomes. The public announcement does not give the number of glaucoma studies, the exact participant count, the search dates, study-selection rules, pooled model details, pollutant-specific concentration ranges, confidence intervals, or study-quality ratings. The cited conference abstract is identified by number, but I could not verify those details in a full accessible report. The headline findings therefore warrant interest, but they cannot yet be audited in the same way as a full journal article. () The ESCRS announcement says that people in the most polluted areas had up to 70% higher odds of glaucoma than those in the least polluted areas. It also reports that glaucoma risk rose by about 8% for each “meaningful step” up in pollution exposure. The announcement does not define that step as an interquartile-range increase, provide a common PM2.5 increment in micrograms per cubic meter, or give a confidence interval for the 8% figure. So the claim that the ESCRS analysis found a pooled odds ratio of 1.08 per interquartile-range increase is not verifiable from its public summary. () A separate 2026 glaucoma-specific review provides useful context, but it is not the ESCRS review. Its abstract reports 18 observational studies, with eight contributing to a PM2.5 meta-analysis. The pooled relative-risk estimate was 1.12, with substantial between-study variation (I² = 78.7%). That result supports an association, but the abstract does not provide a single shared concentration increment that would let readers convert the estimate into one universal number of micrograms per cubic meter. () What does “per interquartile-range increase” mean? The interquartile range is the difference between the 75th-percentile and 25th-percentile exposure levels within a study. An estimate “per interquartile-range increase” means comparing an exposure one study-specific interquartile range higher with the exposure before that increase. That is useful for analyzing each study, but it does not create a common dose across studies. An interquartile range of about 1 microgram per cubic meter is very different from one of 2.9 micrograms per cubic meter. A percentage increase “per interquartile range” therefore cannot be translated into a fixed PM2.5 concentration unless the study’s own interquartile range is known. Examples from published research illustrate the problem: A United Kingdom Biobank analysis reported an odds ratio of 1.06 per interquartile-range increase in PM2.5; the increment was about 1.1 micrograms per cubic meter in that analysis. A related analysis found higher odds of self-reported glaucoma and differences in retinal structure. () A Canadian Longitudinal Study on Aging analysis reported an odds ratio of 1.14 per interquartile-range increase, with the increment reported as about 2.9 micrograms per cubic meter in a systematic review of the study. () A large rural Chinese study reported an odds ratio of 1.07 per 10 micrograms per cubic meter—a fixed increment, not an interquartile range. () A Taiwanese study used yet another measure: cumulative exposure categories based on PM2.5 levels multiplied by months of exposure. Its highest category had an odds ratio of 1.67 compared with its reference category. Those categories are not equivalent to a person breathing an annual average that is a fixed number of micrograms per cubic meter higher. () Bottom line: An interquartile-range result is meaningful only alongside the underlying exposure range. The ESCRS summary does not report enough information to translate its 8% figure into a dependable concentration change. Odds, relative risk, and absolute risk are different The ESCRS summary’s “70% higher odds” is a relative comparison between exposure groups, not a 70-percentage-point increase in the chance that any one person will get glaucoma. An odds ratio compares the odds of an outcome in one group with the odds in another. A relative risk compares their probabilities. For uncommon outcomes, odds ratios and relative risks can be numerically close, but they are not identical. An individual’s absolute risk also depends on their starting risk, which is affected by factors such as age, family history, and other health characteristics. For illustration only: if a group’s starting risk were 2%, an odds ratio of 1.67 would correspond to a risk of about 3.3%, not 72%. This calculation is not an estimate of the risk in the Taiwanese study or in a particular patient; it simply shows why “70% higher odds” does not mean “70% chance of glaucoma.” In the United Kingdom prospective cohort discussed below, roughly 2% of participants developed glaucoma over a median 12.8 years, but that rate should not be applied to every population. () The “up to 70%” figure should therefore be read as a highest-versus-lowest exposure comparison reported in the conference summary, not as a typical effect for every rise in pollution. A specific underlying Taiwanese study found an odds ratio of 1.67 for its highest cumulative exposure category versus its reference category; the available ESCRS summary does not establish that this was the source of its 70% figure or give enough detail to equate the comparisons. () What do the underlying studies show? The evidence is not limited to the conference announcement. Several earlier studies reported positive associations, although they differ in how they measured pollution and glaucoma. Studies with stronger or more objective designs The most useful epidemiological support comes from studies that follow people over time or use clinical examinations rather than relying only on self-report: United Kingdom Biobank, 12-year follow-up: Among 448,253 participants in the particulate-matter analysis, 8,999 incident glaucoma cases were identified over a median 12.8 years. After the study’s broadest adjustment, each study-specific interquartile-range increase in PM2.5 was associated with a 3% higher hazard of glaucoma (hazard ratio 1.03, 95% confidence interval 1.00–1.06). People in the highest exposure quartile—10.57 to 21.31 micrograms per cubic meter—had a 10% higher hazard than those in the lowest quartile—8.17 to 9.29 micrograms per cubic meter. The continuous estimate was small and just met the conventional threshold for statistical significance; the quartile comparison was also modest. () Rural China: In a cross-sectional study of 33,701 adults, each 10-microgram-per-cubic-meter higher PM2.5 level was associated with an odds ratio of 1.07 for glaucoma, with a confidence interval reaching 1.00. The same study reported a larger estimate for primary angle-closure glaucoma, illustrating that subtype findings may differ. () Canada: In the Canadian Longitudinal Study on Aging, higher PM2.5 was associated with glaucoma after adjustment for sociodemographic and health factors. A positive association was also reported in a model that included multiple pollutants, although the study was cross-sectional and its outcomes included self-reported diagnoses. () United Kingdom Biobank, earlier analyses: An earlier analysis found higher odds of self-reported glaucoma with greater PM2.5 exposure. Because exposure and glaucoma status were assessed in a population-based cohort rather than through long-term follow-up of new diagnoses, it cannot establish which came first. () These findings are directionally consistent: several studies found more glaucoma diagnoses or glaucoma-related structural changes at higher PM2.5 exposure. But studies differ in design and outcome, and the 2026 glaucoma-specific review reported high heterogeneity. The po Support the show

    Can Air Pollution Damage the Optic Nerve? A Large Review Links PM2.5 to Higher Glaucoma Risk

  4. 5d ago

    AI Found 21 New Genetic Clues to Glaucoma — Could Some Become Future Drug Targets?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/ai-found-21-new-genetic-clues-to-glaucoma-could-some-become-future-drug-targets Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: AI Found 21 New Genetic Clues to Glaucoma — Could Some Become Future Drug Targets? A study published in npj Genomic Medicine on September 19, 2026 used artificial intelligence to look for glaucoma-related patterns in optical coherence tomography scans, then tested those patterns against genetic data. The researchers reported 21 genetic loci not previously linked to glaucoma, and prioritized 11 genes that might help explain why glaucoma damages the eye. Five of those genes had not previously been reported in glaucoma research. () The work’s main advance is not that artificial intelligence diagnosed glaucoma better. It is that the researchers used measurable patterns of retinal damage—rather than a simple “glaucoma” or “no glaucoma” label—to search for genetic clues. That approach produced a richer biological picture, including a particularly promising signal involving RSPO2 and Wnt signaling in cells that help drain fluid from the eye. But these are genetic leads, not tested glaucoma treatments. The study did not show that changing any of the 11 genes prevents vision loss. The most exciting possibilities still require experiments to establish which genes are truly involved, whether changing them would help or harm, and whether a treatment can reach the right cells safely. What the study found—and what it did not The peer-reviewed article is “Deep-learning-derived glaucoma-related endophenotypes enable novel genome-wide genetic and functional discovery”. It reports 36 genome-wide significant loci in the European-ancestry analysis and 43 in a cross-ancestry analysis. The authors identified 21 loci as previously unreported in glaucoma and used additional analyses to prioritize 11 genes, five of them novel to glaucoma. () A locus is a region of the genome associated with a trait; it may contain several genes. A gene prioritized at a locus is a candidate for explaining the association, not necessarily the gene that causes it. The study therefore offers a set of hypotheses about glaucoma biology. It does not establish that the 21 loci—or any of the 11 genes—cause glaucoma, nor that a drug aimed at them would work. The methodological innovation, in patient-friendly language From a yes-or-no label to a detailed retinal “fingerprint” Many genetic studies classify each participant as having glaucoma or not having glaucoma. That can be a noisy comparison: some people may have undiagnosed disease, and people with glaucoma can have very different patterns and amounts of retinal damage. Instead, these researchers trained machine-learning models on eye scans from people with glaucoma. The models learned patterns in the ganglion cell complex and retinal nerve fiber layer—retinal structures that are affected as glaucoma damages the optic nerve. They then represented those patterns as quantitative traits, or measurable features of the scans. A useful analogy is the difference between asking whether a house is “damaged” and measuring exactly where its walls are cracked, how deep the cracks are, and how much the structure has shifted. The detailed measurements can reveal more about the process behind the damage. These scan-derived traits, which the researchers call endophenotypes, were then linked to genetic differences. They are glaucoma-informed measurements, not a replacement diagnosis or a measure of future vision loss. The study’s full-text manuscript describes two machine-learning model families, labelled AUTO and MOCO, used to produce traits from macular scans. () Reconstructing the research pipeline Train on glaucoma scans: The models were developed using 18,985 clinical optical coherence tomography scans from 8,323 glaucoma patients at Mass Eye and Ear. The earlier manuscript says most had open-angle glaucoma codes, though the training group was not restricted to chart-confirmed primary open-angle glaucoma cases. () Apply the models to UK Biobank: The final peer-reviewed publication reports 39,146 UK Biobank participants with usable genetic and scan-derived data. The ancestry groups were 35,739 European, 1,730 African, and 1,677 Asian participants. The large difference in group sizes means the European results had much greater statistical power. () Run genome-wide association studies: The researchers tested genetic variants against 21 scan-derived traits, separately by ancestry. A genome-wide association study looks across the genome for variants statistically associated with a measured trait. Split samples for discovery and replication: The manuscript describes a 75% discovery / 25% replication split within UK Biobank, followed by meta-analysis. This is useful internal checking, but it is not the same as replication in a fully independent cohort. () Combine results across ancestry groups: They conducted ancestry-specific analyses and then a cross-ancestry meta-analysis, finding 36 significant loci in the European analysis and 43 in the cross-ancestry analysis. Smaller African and Asian sample sizes limit how confidently those group-specific effects can be estimated. Prioritize possible genes and mechanisms: Follow-up analyses included gene-based testing, expression and splicing quantitative trait loci (eQTLs and sQTLs), Bayesian colocalization, Mendelian randomization, and single-cell expression enrichment in eye tissues. These analyses help narrow a locus to possible genes and cell types, but each has its own assumptions and limitations. () Which UK Biobank number should be used? The peer-reviewed publication’s figure is 39,146 participants. An earlier medRxiv abstract reported 47,908, but the manuscript’s detailed ancestry counts—35,739 + 1,730 + 1,677—sum to 39,146. The final publication’s participant number should be used for the peer-reviewed study. The public versions do not clearly explain the origin of the earlier headline figure, so it is safest to treat it as an earlier or inconsistent version figure rather than assume it represents the final analysis. () What “21 new genetic clues” means The authors call 21 loci novel to glaucoma because they had not previously been reported as associated with glaucoma or established glaucoma-related traits. “Novel” here does not mean the genes were newly discovered, that the DNA changes are unique to glaucoma, or that the genes’ roles in the body are now understood. The 11 prioritized genes were: EIF3E, LIN52, NPLOC4, PBLD, RSPO2, SLC25A16, TSPAN10, DYNC1I2, SLC25A12, ATOH7, and C14orf39. The paper identifies RSPO2, EIF3E, LIN52, DYNC1I2, and SLC25A12 as the five genes not previously reported in glaucoma. It also notes prior glaucoma-related or eye-trait evidence for some of the other genes, including ATOH7, C14orf39, NPLOC4, TSPAN10, PBLD, and SLC25A16. () The 11 prioritized genes: biology, eye-cell evidence, and drug prospects The cell evidence below refers to the study’s expression and enrichment analyses—not proof that a gene causes disease in that cell. The single-cell reference data came from non-diseased human eye tissues, and for several genes the article does not identify a particular eye-cell type as the key location. () For the full table, please open this article on visualfieldtest.com. Two shared regions make some gene assignments especially uncertain Several prioritized genes sit in the same genetic region. For example, DYNC1I2 and SLC25A12 share a locus in the study’s prioritization table; both may be plausible candidates, but the association does not establish which gene—or whether both—accounts for the signal. A similar caution applies to the chromosome 10 region involving ATOH7, PBLD, and nearby genes. These are reasons for follow-up experiments, not reasons to discard the findings. () The main biological themes Wnt signaling and aqueous outflow: the clearest treatment-oriented lead Aqueous humor is the clear fluid inside the eye. It normally drains through the trabecular meshwork. If drainage meets too much resistance, eye pressure can rise. Lowering pressure is an established way to slow glaucoma damage. RSPO2 is notable because it can strengthen Wnt signaling and the study found it in trabecular-meshwork and other anterior-segment fibroblasts, as well as optic-nerve-head fibroblasts. That puts a biologically plausible candidate in cells involved in tissue structure and outflow. Importantly, earlier laboratory work supports a role for canonical Wnt signaling in the trabecular meshwork and pressure regulation. In experimental models, blocking Wnt signaling raised pressure, and another study found that Wnt activation could reverse some abnormal features of trabecular-meshwork cells. Those results strengthen the general Wnt–outflow hypothesis—but they do not prove RSPO2 causes glaucoma or establish whether RSPO2 itself should be increased or decreased. () That direction matters. RSPO2 boosts Wnt signaling, and the prior eye studies suggest that too little canonical Wnt activity may be harmful in the trabecular meshwork. A simple plan to block RSPO2 could therefore be wrong. The best therapeutic idea, if the genetics is confirmed, may be to restore or tune local Wnt signaling, rather than turn it off across the body. Retinal ganglion-cell vulnerability, axonal transport, and mitochondria The study’s cross-ancestry gene-expression enrich Support the show

    AI Found 21 New Genetic Clues to Glaucoma — Could Some Become Future Drug Targets?

  5. Sep 24

    PRESERFLO vs Trabeculectomy: A New Randomized Trial Tests Which Glaucoma Surgery Really Lowers Pressure Better

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/preserflo-vs-trabeculectomy-a-new-randomized-trial-tests-which-glaucoma-surgery-really-lowers-pressure-better Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: PRESERFLO vs Trabeculectomy: A New Randomized Trial Tests Which Glaucoma Surgery Really Lowers Pressure Better The new trial reports an important change over time: PRESERFLO had lower pressure early after surgery, while trabeculectomy achieved lower pressure at 3 and 12 months. But the published abstract does not provide the exact pressure values or confidence intervals needed to calculate the size of that difference. Here is what the study does—and does not—establish. The short answer The new trial supports trabeculectomy as the stronger pressure-lowering choice when the main goal is a very low pressure. It does not show how many millimeters of mercury a patient gives up by choosing PRESERFLO, because its abstract does not provide the arm-by-arm pressure readings needed to calculate that difference. Across earlier comparative evidence, the average long-term pressure advantage for trabeculectomy has generally been about 1 to 3 mmHg. That difference may matter more when glaucoma is advanced and the target is in the low teens—or lower. PRESERFLO remains a reasonable option for some people whose target is less stringent and who value its design and potential reduction in certain postoperative risks. But it is still bleb-forming filtration surgery: it is not free of scarring, needling, follow-up, or late infection risk. The new trial was published on September 19, 2026, just five days before this article’s date, September 24, 2026. It is an accepted, early online article that may receive final editorial changes. It randomized 99 people: 51 to PRESERFLO MicroShunt with mitomycin C and 48 to trabeculectomy with mitomycin C. The abstract reports lower early pressure with PRESERFLO and lower pressure with trabeculectomy at 3 and 12 months. () What the new randomized trial did Who was studied—and what we can verify The study included adults with primary open-angle glaucoma (POAG) or pseudoexfoliation glaucoma (PEXG) whose disease was progressing despite maximum tolerated treatment. Eligibility required worsening visual-field results and pressure remaining above the patient’s target despite topical and oral medicines. The study was conducted at one center in Poland, with recruitment from April 2023 to October 2024 and 12 months of follow-up. () Some details requested by patients—including the exact numbers of POAG versus PEXG participants, the distribution of glaucoma severity, mean baseline pressure, average number of baseline medications, and the numerical target pressure—are not included in the searchable abstract and methods text available for this review. The full paper may contain additional figures or tables, but those values are not reproduced here rather than guessed. The study says that disease progression was assessed with visual fields, but that alone does not establish how many participants had mild, moderate, or advanced damage. () How surgery and randomization were handled The researchers used folded allocation slips to assign patients in a 1:1 ratio immediately before surgery. The slips were prepared by an investigator who did not enroll participants. There was no blocking or stratification, and neither surgeons nor participants could be blinded; outcome assessors were not formally blinded either. The study was registered after recruitment had begun: the paper says registration occurred on March 16, 2026, after enrollment ended in October 2024. The authors say the protocol and analysis plan had been set before recruitment. Retrospective registration and unblinded assessment do not invalidate the findings, but they are reasons to interpret a small, single-center trial cautiously. () A single experienced surgeon performed the procedures. Mitomycin C (MMC) was applied with sponges for two minutes at either 0.2 mg/mL or 0.4 mg/mL, with the concentration chosen by the surgeon based on anticipated scarring risk. In the trabeculectomy group, the surgeon created a scleral flap, used a Kelly punch, and secured the flap with four nylon sutures. In the PRESERFLO group, no intraluminal stent or ripcord was used. Cataract surgery was combined with filtration surgery in 37 of 51 PRESERFLO cases and 33 of 48 trabeculectomy cases. () Patients continued their glaucoma medicines through the day of surgery; there was no medication washout. The study used antibiotic and steroid treatment after surgery. Both procedures still require postoperative assessment of pressure and the filtering bleb; the exact medication-adjustment and visit schedule is not available in the abstracted text. () Pressure results: what is known and what is not The published abstract reports the direction of the result, but not the exact mean pressures, standard deviations, confidence intervals, or between-group effect sizes for each visit. The table below separates what the abstract says from numbers that cannot be verified from it. For the full table, please open this article on visualfieldtest.com. These are reporting limits of the abstracted information, not evidence that the full paper contains no numerical table. Without arm-specific baseline and follow-up means—and their variability—it is not possible to calculate reliable absolute reductions, percentage reductions, confidence intervals, or a standardized effect size for this 99-person trial. Nor is it possible to infer how many individuals crossed a particular pressure threshold from a group average. () How large is the pressure difference in the broader evidence? The new study fits a pattern already seen in comparative research. A 2025 meta-analysis of 10 comparative studies found that trabeculectomy achieved a mean pressure about 1.59 mmHg lower than PRESERFLO and a larger pressure reduction from baseline. A later meta-analysis covering 14 studies and 2,229 patients estimated that pressure after PRESERFLO was 1.44 mmHg higher than after trabeculectomy (95% confidence interval, 0.64 to 2.24 mmHg); pressure reduction was 2.73 mmHg smaller with PRESERFLO (95% confidence interval, 1.61 to 3.84 mmHg smaller). These pooled results had moderate-to-high variation between studies and largely reflect follow-up of up to two years—not a guaranteed difference for an individual patient. () The largest earlier randomized comparison enrolled 527 people with POAG: 395 received PRESERFLO and 132 trabeculectomy. At one year, reported mean pressure reductions were 29.1% with PRESERFLO and 45.4% with trabeculectomy. Surgical success—defined in that trial as at least a 20% reduction from baseline without increasing medicines—was also lower in the PRESERFLO group at one year. This was a different trial, with different participants and methods, so its figures should not be substituted for the new trial’s missing values. () Bottom line on pressure: The comparative evidence generally favors trabeculectomy for achieving the lowest pressure. The best pooled estimate is a difference of roughly 1 to 2 mmHg in postoperative pressure, with some studies showing a larger gap. The new randomized trial adds support to that direction, but the abstract alone does not tell us the trial’s exact difference. Why the early result could reverse Mechanistic explanation—inference, not a finding proven by the trial: PRESERFLO is an 8.5-millimeter tube with a 70-micrometer lumen. That lumen creates resistance to fluid flow and is intended to reduce excessive early drainage. Trabeculectomy instead makes an opening beneath a surgically fashioned scleral flap, which the surgeon can adjust using sutures; those sutures can sometimes be loosened or cut with laser after surgery. The two operations therefore manage early flow differently. () A lower pressure immediately after PRESERFLO surgery does not necessarily mean it will maintain a lower pressure later. As healing proceeds, scarring around the tube outlet or within the bleb can restrict drainage. A trabeculectomy may, by contrast, be adjusted after surgery to improve filtration. The main trial’s findings are consistent with these possible explanations, but they do not prove that the tube’s fixed lumen or bleb scarring caused the reversal. Differences in postoperative adjustment, steroid treatment, healing, or the cataract operations performed alongside filtration surgery could also contribute. The trial did not use a PRESERFLO intraluminal stent, and it used MMC at the surgeon’s choice of two concentrations. Because the dose varied, any claim that the results demonstrate a single optimal MMC exposure—or that MMC explains the reversal—would go beyond the reported evidence. () Complete and qualified success: useful, but not enough on its own Complete success usually means reaching a specified pressure target without glaucoma medicines. Qualified success means reaching the target with medicines permitted. These labels are only meaningful when the pressure cutoff, required percentage reduction, and rules for further surgery are clear. For the new trial, the abstract says complete success at six months was significantly higher after trabeculectomy and that qualified success was comparable between groups over follow-up. It does not give the exact percentages or the pressure thresholds behind those results. So it can Support the show

    PRESERFLO vs Trabeculectomy: A New Randomized Trial Tests Which Glaucoma Surgery Really Lowers Pressure Better

  6. Sep 22

    Can an Implant-Free Laser Procedure Free Glaucoma Patients From Eye Drops? New 2-Year ELIOS Results

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-an-implant-free-laser-procedure-free-glaucoma-patients-from-eye-drops-new-2-year-elios-results Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can an Implant-Free Laser Procedure Free Glaucoma Patients From Eye Drops? New 2-Year ELIOS Results Bottom line The new 24-month ELIOS excimer laser trabeculostomy results are encouraging—but they answer a narrower question than many headlines suggest. The study shows that cataract surgery combined with ELIOS can produce a sustained reduction in unmedicated eye pressure and allow many patients to stop glaucoma drops for at least two years. In the pivotal study, mean unmedicated diurnal eye pressure fell from approximately 24.5 millimeters of mercury at baseline to 16.8 millimeters of mercury at 24 months, and 82.0% of patients were medication-free around month 23. Gallardo et al., 24-month pivotal study () However, the central limitation is important: there was no concurrent cataract-surgery-only control group. The trial was a prospective, single-arm study that compared its results with historical performance goals derived from earlier minimally invasive glaucoma surgery trials. My interpretation is: ELIOS plus cataract surgery works as a combined treatment. It probably provides additional pressure lowering beyond cataract surgery alone. The most reasonable estimate of the additional ELIOS effect at 24 months is approximately 1.5 to 2.5 millimeters of mercury, with a plausible range of roughly 1 to 3 millimeters of mercury. The medication-free benefit may be real and clinically valuable, but the exact size of that benefit is less certain without a randomized control arm. ELIOS appears best suited to patients with mild-to-moderate primary open-angle glaucoma who already need cataract surgery. It should not be viewed as a replacement for trabeculectomy or tube surgery in patients needing an eye pressure below 12 millimeters of mercury, or in many patients with advanced glaucoma. The original paper was published online on September 8, 2026, and the two-year results were presented at the European Society of Cataract and Refractive Surgeons Congress in London from September 10 through September 14, 2026. () What is ELIOS? ELIOS is an implant-free form of excimer laser trabeculostomy. Instead of leaving a stent inside the eye, the procedure uses a 308-nanometer xenon chloride excimer laser to create small openings through the trabecular meshwork, the eye’s main drainage tissue. These openings are intended to provide a more direct route for fluid to enter Schlemm’s canal and then reach the eye’s natural collector channels. The current ELIOS treatment creates: 10 microchannels Each approximately 210 micrometers in diameter Across approximately 90 to 110 degrees of the nasal trabecular meshwork After cataract removal and placement of an intraocular lens The procedure is performed through a small corneal incision under gonioscopic visualization. It is described as nonthermal photoablation, meaning that tissue is removed by breaking molecular bonds rather than by burning or coagulating tissue. () The 2026 pivotal study: exact design Study design The pivotal trial was: Prospective Multicenter Nonrandomized Single-arm Conducted under a United States investigational device exemption Registered as NCT04899063 Conducted at 20 United States sites Treatment period: approximately June 2021 through July 2023 Published as a 24-month report in Ophthalmology Glaucoma The study included 318 patients who underwent cataract surgery followed by ELIOS. ClinicalTrials.gov study record () How many patients completed 24 months? This point requires careful wording. The original paper’s abstract reports 318 treated patients and presents the 24-month efficacy percentages using figures that correspond closely to a 318-patient denominator: 84.2% at 12 months corresponds to approximately 268 of 318 76.1% at 24 months corresponds to approximately 242 of 318 82.0% medication-free around month 23 corresponds to approximately 261 of 318 A conference report described the study as involving 318 patients who completed the two-year cohort, but the PubMed abstract does not provide a separate conventional patient-flow table showing enrollment, losses to follow-up, exclusions, and the exact number available at every visit. Therefore, the most defensible statement is: > 318 patients underwent the combined procedure, and the published endpoint percentages appear to use the 318-patient analysis population; the publicly visible abstract does not separately document a detailed 24-month completer denominator. That distinction matters because a study can report an analysis percentage based on available or imputed data without every patient completing every examination. () Who was included? The study enrolled adults who had: Age of at least 45 years Mild-to-moderate primary open-angle glaucoma An operable age-related cataract Best-corrected visual acuity of approximately 20/40 or worse, according to the trial eligibility description Medicated eye pressure of 24 millimeters of mercury or less Treatment with one to three glaucoma medications Unmedicated mean diurnal eye pressure between 22 and 34 millimeters of mercury after medication washout The study therefore did not primarily test ELIOS in patients with advanced disease, very low target pressures, or highly medication-resistant glaucoma. () Baseline medication use The mean baseline medication burden reported in the 12-month conference abstract was approximately: 1.5 medications Standard deviation approximately 0.7 medications This is important. The study population was not made up mainly of patients taking four or five medications. It was largely a mild-to-moderate glaucoma population with a modest medication burden. () Baseline eye pressure The study reported: Mean medicated eye pressure at screening: 17.05 ± 3.01 millimeters of mercury Mean unmedicated diurnal eye pressure at baseline: 24.53 ± 2.51 millimeters of mercury The unmedicated diurnal measurement was taken after glaucoma medications had been stopped according to the study protocol. () Washout protocol The public abstract confirms that patients had to reach the required unmedicated diurnal eye pressure range after washout. However, the abstract does not list the exact medication-specific washout durations—for example, the number of days required for prostaglandin analogues, beta blockers, or carbonic anhydrase inhibitors. That information should not be inferred from another trial. Hydrus and iStent pivotal trials also used medication washouts, but their exact schedules and visit procedures were not necessarily identical to those used in ELIOS. The ELIOS publication therefore supports the statement that the baseline pressure was measured after medication washout, but the publicly available abstract does not allow a complete reconstruction of the washout timetable. () Cataract-surgery procedure Patients underwent: Standard phacoemulsification cataract extraction Placement of an intraocular lens ELIOS excimer laser trabeculostomy after the cataract portion was completed The trial therefore studied a combined operation, not ELIOS in isolation. () The prespecified primary endpoints The study had two co-primary efficacy endpoints at both 12 and 24 months. Endpoint 1: percentage achieving at least a 20% pressure reduction The percentage of patients had to achieve at least a 20% reduction in unmedicated mean diurnal eye pressure from baseline. The prespecified performance goals were: 12 months: greater than 79% 24 months: greater than 68.5% Endpoint 2: mean change in unmedicated diurnal eye pressure The mean reduction in unmedicated diurnal eye pressure had to meet: 12 months: at least 7.2 millimeters of mercury 24 months: at least 6.15 millimeters of mercury These were not comparisons against a contemporaneous cataract-only group. They were comparisons against historical performance goals derived from cataract-only arms in prior minimally invasive glaucoma surgery trials. () Exact 24-month results The results reported in the original paper were: For the full table, please open this article on visualfieldtest.com. The 12-month result represented approximately a 34.5% reduction, while the 24-month change represented approximately a 30% reduction from the washed-out baseline pressure, depending on whether one uses the reported group means or the paired endpoint estimates. A small arithmetic issue is worth noting: the reported mean pressure at each visit does not subtract exactly from the reported mean change because endpoint analyses may use different available-patient populations or model-based estimates. The two numbers should therefore not be forced into a simple subtraction equation. The most important correction to circulating coverage is this: > 24.53 millimeters of mercury was the baseline unmedicated pressure, not the 24-month pressure. The reported 24-month mean pressure was 16.76 millimeters of mercury. The original paper is the appropriate source for these values. () How durable was the medication-free result? At approximately month 23, 82.0% of patients were reported to be medication-free. That is a strong result, but it should be interpreted carefully. “Medication-free” does not mean that the glaucoma was cured. It means that, at that point in follow-up, the patient was not using pressur Support the show

  7. Sep 21

    A Glaucoma Laser Treatment Lowered Eye Pressure for 4 Years Without Cutting Into the Eye

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/a-glaucoma-laser-treatment-lowered-eye-pressure-for-4-years-without-cutting-into-the-eye Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: A Glaucoma Laser Treatment Lowered Eye Pressure for 4 Years Without Cutting Into the Eye Evidence review current to September 21, 2026 Bottom line The newest 48-month results for femtosecond laser image-guided high-precision trabeculotomy, called FLigHT, are encouraging but still preliminary. In the original first-in-human cohort: 18 eyes from 12 patients were treated. 15 eyes remained evaluable at 48 months. Mean medicated intraocular pressure decreased from 21.4 ± 4.6 millimeters of mercury to 14.9 ± 2.6 millimeters of mercury. That is approximately a 27% reduction, or about 6.5 millimeters of mercury. Mean glaucoma medication use decreased only modestly, from 2.1 to 1.8 medications, and the reduction was not statistically significant. The study did not use medication washout. The treated channels reportedly remained visible and patent on gonioscopy and anterior-segment optical coherence tomography after four years. No serious FLigHT-related adverse events were reported in the available 48-month reports. The key qualification is that this was a small, single-center, nonrandomized, single-arm study without a control group. The 48-month data have been presented at the European Society of Cataract and Refractive Surgeons meeting, but a complete peer-reviewed 48-month publication was not available in the public sources reviewed. My assessment is: > FLigHT has shown a credible four-year durability signal and pressure lowering in the general range of trabecular minimally invasive glaucoma surgery. It has not yet demonstrated that it is better than selective laser trabeculoplasty, equivalent to established minimally invasive glaucoma surgery, or reliably medication-sparing. The most likely future role is not replacing every glaucoma procedure. It is becoming a treatment option between selective laser trabeculoplasty and incisional minimally invasive glaucoma surgery, particularly for patients with open-angle glaucoma who need pressures in the low-to-mid teens but do not yet require the very low pressures often sought with trabeculectomy. --- What was newly reported at the 2026 European Society of Cataract and Refractive Surgeons meeting? The 44th European Society of Cataract and Refractive Surgeons Congress was held in London from September 11 through September 15, 2026. The 48-month FLigHT update was presented by Zoltan Nagy and colleagues as ePoster POGAU064. Ophthalmology Times conference report Media MICE conference report () The 48-month results For the full table, please open this article on visualfieldtest.com. The pressure reduction was statistically significant, with a reported P value below .001. However, the available conference reports do not provide the full patient-level dataset, confidence intervals, individual pressure trajectories, or a complete breakdown of medication classes. How many patients were still being followed? The publicly described 48-month result is based on 15 of the original 18 treated eyes, which represents an eye-level retention of approximately 83%. The accessible reports do not clearly identify: How many individual patients those 15 eyes represented The exact reason each missing eye was not included Whether missing eyes were lost to follow-up, had incomplete testing, or were excluded for another reason Therefore, the most defensible statement is: > Three of 18 treated eyes were not included in the 48-month analysis. Patient-level attrition is not fully reported in the public conference coverage. This matters because small studies can look better when participants with less favorable results are disproportionately lost from follow-up. --- What was the original first-in-human study? The first human study was a: Prospective Nonrandomized Single-center Single-arm Interventional safety study It was performed at Semmelweis University in Budapest, Hungary, with treatment performed in September and October 2020. The study was registered as NCT04949802. ClinicalTrials.gov study record Nagy et al., 24-month primary report () Patients and glaucoma severity The cohort included 18 eyes from 12 patients with open-angle glaucoma. The later three-year conference report described the group as: Approximately 33% mild glaucoma Approximately 28% moderate glaucoma Approximately 39% severe glaucoma Mean age: 72.2 ± 9.7 years Approximately 92% female Approximately 89% pseudophakic, meaning they had already undergone cataract surgery The cohort was small and demographically narrow. All participants were reported to be Caucasian. This limits how confidently the results can be generalized to younger patients, different ethnic groups, angle anatomy variations, or patients with secondary forms of glaucoma. European Glaucoma Society 2024 abstract book () The original study excluded eyes with previous glaucoma procedures, including: Selective laser trabeculoplasty Glaucoma implants Previous glaucoma surgery Eye conditions that would prevent adequate visualization of the trabecular meshwork This means the first-in-human results primarily describe untreated trabecular anatomy, apart from ongoing glaucoma medications. Baseline pressure and medications For the longer-term cohort, baseline mean intraocular pressure was: 21.4 ± 4.6 millimeters of mercury Patients were using: 2.1 ± 1.0 glaucoma medications at baseline The published 24-month report used a slightly different analytic sample and reported a baseline pressure of approximately 22.3 millimeters of mercury, falling to 14.5 millimeters of mercury at 24 months. Mean medication use decreased from approximately 2.2 to 2.0 medications, a change that was not statistically significant. Nagy et al., 24-month primary report () --- Exactly how does FLigHT work? FLigHT is best understood as a laser-created trabeculotomy performed through an intact cornea. The ViaLuxe system combines: High-resolution gonioscopic imaging Optical coherence tomography imaging Computer-controlled femtosecond laser delivery The system identifies the trabecular meshwork and Schlemm’s canal. It then focuses femtosecond laser pulses into the drainage tissue. What was created in the first human study? Each treated eye received one channel in the nasal angle. The reported dimensions were approximately: 500 micrometers wide 200 micrometers high Approximately 400 micrometers deep in the later technical description The treatment used approximately 400 femtosecond pulses at a wavelength of 1080 nanometers. The channel crossed the trabecular meshwork and entered Schlemm’s canal. The first human channel treated only about 5 degrees of the angle. European Glaucoma Society 2024 abstract book Nagy et al., 24-month primary report () Is the anterior chamber entered? There are two different meanings of “entering the eye.” No surgical instrument enters the anterior chamber The procedure does not require: A corneal incision A paracentesis A surgical blade A cannula A goniotomy blade An implant The femtosecond laser is focused through the intact cornea. In that sense, the eye is not surgically opened. But the laser creates a channel that communicates with the anterior chamber The intended channel begins at the anterior-chamber side of the trabecular meshwork and crosses into Schlemm’s canal. Therefore, FLigHT is not biologically “non-penetrating.” It creates a real internal opening through the trabecular tissue. The more precise description is: > FLigHT is externally incision-free but internally channel-forming. That distinction is important. Calling it “noninvasive” describes the absence of an external incision; it does not mean that the trabecular tissue is left intact. Anesthesia and preparation In the original first-in-human protocol: Topical anesthetic eye drops were used. Pilocarpine 2% was administered approximately one hour before treatment to constrict the pupil. Oral acetazolamide, 250 milligrams, was given two hours before treatment as a precaution against an early pressure spike. A specialized coupling lens and gonioscopic interface were placed on the cornea. The acetazolamide was a precaution used in the first human cases and should not automatically be assumed to be required for every commercial treatment. How long does treatment take? The first published study did not provide a clear standardized treatment-time measurement. Reports from the first commercial cases describe approximately two to three minutes of laser treatment per eye, with some clinic reports describing the complete procedure as approximately five minutes. The Ophthalmologist clinical report () This is considerably shorter than most operating-room-based glaucoma procedures, although total visit time includes preparation, imaging, docking, verification, and post-treatment assessment. Can it be repeated? The ViaLuxe system is designed to allow: More than one channel Customized channel placement Treatment in additional areas of the angle Retreatment if pressure later rises However, this is an important distinction: > Retreatment is a technical possibility, not yet a clinically validated long-term strategy. The first-in-human cohort received one channel per eye. There is not yet strong clinical evidence showing how much additional pressure lowering is obtained by creating a second or third c Support the show

    A Glaucoma Laser Treatment Lowered Eye Pressure for 4 Years Without Cutting Into the Eye

  8. Sep 16

    Can We Improve Fluid Absorption Around a Trabeculectomy Bleb? Evidence, Lymphatic Drainage, and Plausible Ways to Reduce Discomfort

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-we-improve-fluid-absorption-around-a-trabeculectomy-bleb-evidence-lymphatic-drainage-and-plausible-ways-to-reduce-discomfort Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can We Improve Fluid Absorption Around a Trabeculectomy Bleb? Evidence, Lymphatic Drainage, and Plausible Ways to Reduce Discomfort Literature reviewed through September 16, 2026. Introduction A trabeculectomy intentionally creates a new pathway for aqueous humor to leave the eye. The fluid passes through the scleral flap and collects beneath the conjunctiva, creating a filtering bleb. The bleb is not simply a passive “bubble.” It is a reservoir connected to surrounding conjunctival tissue, lymphatic vessels, blood vessels, and the deeper orbital tissues. For a person with a functioning trabeculectomy and a previously measured intraocular pressure around 7 millimeters of mercury, the key question is: > Can fluid already present outside the eye be cleared more efficiently so the bleb becomes less raised or uncomfortable, without increasing flow through the surgical opening or causing a clinically important pressure reduction? The answer is biologically plausible but clinically unproven. The strongest modern evidence indicates that conjunctival lymphatic vessels are a genuine downstream drainage route from subconjunctival blebs. However, deliberately increasing lymphatic drainage could also reduce resistance downstream, increase total filtration, and lower intraocular pressure further. This is particularly relevant when the pressure is already low. For many patients, discomfort from a functioning bleb is caused less by failure to absorb fluid and more by: the shape or location of the bleb; eyelid friction during blinking; disruption of the tear film; a small corneal epithelial defect or corneal dellen; surrounding conjunctival swelling; inflammation; or clinically significant hypotony. Therefore, the most rational approach is to separate three goals: Reduce ocular-surface discomfort without changing filtration. Correct an abnormal bleb shape while preserving as much filtration as possible. Investigate downstream lymphatic clearance as a future treatment target, rather than attempting to stimulate it independently at home. --- The Complete Fluid Pathway The pathway in simple terms Step 1: Production in the eye Aqueous humor is produced by the ciliary body and enters the anterior chamber. In an untreated eye, most aqueous humor leaves through the trabecular meshwork and Schlemm canal. Trabeculectomy bypasses much of this conventional resistance. Step 2: Passage through the surgical opening A trabeculectomy creates a controlled route through the sclera. Fluid may pass: beneath the scleral flap; around the edges of the flap; through the sclerostomy; and through adjacent scleral or connective tissue planes. The scleral flap, its sutures, the size of the opening, and postoperative scarring determine much of the resistance before fluid reaches the bleb. This is the important distinction in the question: improving downstream clearance would not necessarily enlarge the internal opening, but it could reduce pressure behind the flap and thereby alter the pressure gradient across it. Step 3: Distribution within the bleb Once outside the eye, aqueous humor may occupy: a relatively large fluid-filled cavity; multiple smaller cavities; microcysts within the bleb wall; loose connective-tissue spaces; or a combination of these. Anterior segment optical coherence tomography studies have shown that functioning blebs may contain multiple internal layers, microcysts, and fluid-filled cavities. Larger internal fluid spaces and greater bleb dimensions are often associated with lower postoperative pressure, although appearance alone does not reliably predict pressure or comfort. () A raised bleb therefore does not automatically mean that fluid is “trapped” abnormally. Some elevation is the visible expression of successful filtration. Step 4: Clearance from the subconjunctival tissues There are several possible downstream routes. Route A: Conjunctival lymphatic drainage This is now the most strongly supported organized drainage route. The conjunctiva contains a rich lymphatic network. Experimental studies have shown that fluid injected into the subconjunctival space can enter irregular, sausage-shaped channels containing valve-like structures. These pathways express lymphatic markers such as podoplanin and Prospero-related homeobox 1, but do not match the pattern of ordinary blood vessels. () A 2019 prospective cross-sectional human study examined 13 eyes after trabeculectomy. Trypan blue injected into the anterior chamber stained lymphatic structures in eight eyes. Those eyes had a mean intraocular pressure of 12.6 millimeters of mercury, compared with 23.6 millimeters of mercury in the five eyes without visible lymphatic staining. Greater lymphatic extent was associated with lower pressure. This supports a functional relationship, but the study was small and observational. () A 2021 live-human imaging study found valve-containing intraconjunctival pathways after subconjunctival tracer injection. In the timed group, visible pathways appeared in seven of ten eyes after approximately 16 minutes, whereas they were not visible immediately after injection. The findings support delayed movement into lymphatic-like pathways, although the participants generally had retinal disease and repeated ocular injections rather than uncomplicated, healthy conjunctiva. () The lymphatic route likely continues toward regional lymph nodes and then returns fluid to the venous circulation. A mouse study using quantum-dot tracers detected signal in the submandibular lymph node approximately six hours after ocular injection, providing direct evidence of an eye-to-lymph-node drainage route in that species. () Route B: Diffuse movement toward blood vessels Blood vessels may still absorb some fluid from the conjunctival tissue through ordinary interstitial and vascular exchange. However, they appear less likely to be the principal organized bulk-flow pathway from a filtering bleb. In porcine, bovine, and human postmortem eyes, tracer-filled subconjunctival outflow pathways were associated with lymphatic markers and did not co-localize with the blood-vessel marker CD31. These studies do not prove that blood vessels absorb no fluid; they show that the distinctive valve-containing pathways from blebs are more consistent with lymphatics than with blood vessels. () A reasonable mechanistic interpretation is: Lymphatics provide directed, low-pressure bulk drainage. Blood vessels may contribute to diffuse absorption from the surrounding tissue. The relative contribution probably varies with bleb structure, inflammation, scarring, and local vascularity. Route C: Diffuse movement through tissue planes Fluid may spread through the conjunctival stroma and Tenon tissue before entering lymphatic or vascular channels. This is not a separate “drain” so much as the tissue pathway leading to the drains. Fibrosis, a dense extracellular matrix, local tissue compression, and isolated fluid pockets can all increase resistance to movement through these planes. Route D: Evaporation through the ocular surface Evaporation from the tear film is not a credible major route for clearing aqueous humor from a functioning bleb. It may influence superficial surface moisture, but it cannot reasonably account for sustained aqueous filtration from the eye. This is a mechanistic inference from the continuous volume of aqueous humor entering the bleb and the observed lymphatic outflow pathways. () --- What Limits Downstream Clearance? Downstream clearance can be limited at several different levels. A. Few or poorly connected lymphatic vessels The bleb may have limited access to nearby lymphatic channels. Human post-trabeculectomy studies suggest that lymphatic connections are variable: some blebs show obvious connections while others do not. () B. Scar tissue and altered extracellular matrix Fibrosis can: isolate the bleb from surrounding lymphatics; compress small lymphatic channels; create a thick capsule around a fluid pocket; reduce tissue compliance; and force fluid to collect in a narrow, high-pressure compartment. C. Antimetabolite-related lymphatic suppression Mitomycin C and 5-fluorouracil are used to reduce fibroblast proliferation and scarring after glaucoma surgery. Animal studies suggest that these drugs can also reduce subconjunctival lymphatic branching and length. In mouse eyes, mitomycin C and 5-fluorouracil reduced lymphatic presence in some experimental protocols, whereas vascular endothelial growth factor C increased it. () This creates an important biological tradeoff: > The same tissue-modifying strategy that helps preserve a filtering bleb by reducing scar formation may also reduce the lymphatic network available to clear fluid from it. That does not mean mitomycin C was a mistake or that it should be reversed. It means that fibrosis control and lymphatic preservation are separate biological objectives. D. Downstream venous or lymphatic pressure Lymphatic drainage is not determined only by the number of vessels. Flow also depends on: tissue pressure; lymphatic valve function; contraction of collecting lymphatics; pressure in downstream lymphatic channels; nea Support the show

    Can We Improve Fluid Absorption Around a Trabeculectomy Bleb? Evidence, Lymphatic Drainage, and Plausible Ways to Reduce Discomfort
See All (259)

Ratings & Reviews

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like